Haleon Cuts Full-Year Organic Revenue Growth Outlook to Around 2.5%
Haleon lowered its full-year organic revenue growth outlook to around 2.5%; weak cough medication sales weighed on results. Shares fell.
Story updates
08:59:59 AM UTC
SquawkNews
04:57 AM EDT, 10/29/2026 (MT Newswires) -- Haleon (HLN) reported Q3 revenue Thursday of 2.87 billion
By Aimee LookAdvil maker Haleon's shares dove after the company cut its outlook for the year and weak sales for cough medications weighed on results.The company, which spun out of pharmaceutical group GSK in 2022, said it now expects full-year organic revenue growth around 2.5%. Haleon at its half…